Cohort characteristics for test of construct validity.
| Cohort Characteristics | JIA Group | Control Group |
|---|---|---|
| N | 76 | 91 |
| Females | 53 (69.7) | 39 (42.9) |
| Mean age at baseline, yrs (± SD) | 12.22 (± 3.0) | 13.45 (± 2.6) |
| JIA subcategories | ||
| Oligoarticular | 46 (61) | — |
| Polyarticular | 26 (34) | — |
| Systemic | 3 (4) | — |
| Psoriatic | — | — |
| Enthesitis-related arthritis | 1 (1) | — |
| Unknown | — | — |
| Medical treatment at time of orofacial examination | ||
| No medication | 34 (45) | — |
| NSAID | 10 (13) | — |
| Methotrexate | 24 (32) | — |
| Leflunomide | 6 (8) | — |
| Systemic steroid | — | — |
| Anti-TNF | 26 (34) | — |
| Anti–IL-6 | 3 (4) | — |
| Single drug | 22 (29) | — |
| Combination of 2 drugs | 16 (21) | — |
| Combination of 3 drugs | 3 (4) | — |
Values are n (%) unless otherwise specified. JIA: juvenile idiopathic arthritis; NSAID: nonsteroidal antiinflammatory drug; TNF: tumor necrosis factor; IL: interleukin.